Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 469 of 6351
-
Experimental drug aims to boost immune attack on aggressive brain tumors
Disease control Recruiting nowThis phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growi…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising new combo aims to extend life in rare, Tough-to-Treat cancer
Disease control Not yet recruitingBackground Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) origin are rare and highly aggressive diseases. The recommended first-line (L1) treatment is platinum-etoposide combination therapy, which has a progression-free survival (PFS) of only 4…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug IBI3003 enters first human trials for Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to ex…
Phase 1/2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThe purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 …
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy offers hope for patients with inoperable liver cancer
Disease control Recruiting nowThis study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule. By comparing the objective response rate (ORR) and other data with tho…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for tough esophageal cancer: drug combo targets gene mutations
Disease control Not yet recruitingA Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined with Benmelstobart versus Toripalimab Combined with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Ce…
Phase 3 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New study aims to protect female asylum seekers from sexual violence
Prevention Not yet recruitingWomen seeking asylum (WSA) are overexposed to sexual violence (SV) in their countries of origin, along migration routes, and within host countries. This overexposure does not cease upon arrival in host countries; on the contrary, the first months following arrival are characteris…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to tame rare artery disease
Disease control Not yet recruitingTakayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular compli…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to fight advanced colorectal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer. It will also evaluate long-term survival outcomes and explore potenti…
Phase 2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New immune combo aims to fight lymphoma without chemo
Disease control Not yet recruitingOpen-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gut bacteria boost? probiotic added to chemo in breast cancer trial
Disease control Recruiting nowTo evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a tongue swab replace sputum tests for TB?
Diagnosis Not yet recruitingTuberculosis (TB) remains the leading cause of death from a single infectious agent globally, with millions of people still undiagnosed or diagnosed late. Conventional case-finding strategies rely heavily on symptom screening using the WHO Four-Symptom Screen ((W4SS; comprising a…
Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
Could a blood thinner and heart pill prevent deadly liver complications?
Disease control Recruiting nowThe APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients wi…
Phase 4 • Sponsor: Asian Institute Of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Artificial cornea implant aims to reverse blindness in 54-Patient trial
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled (1:1) non-inferiority clinical trial. A total of 54 subjects are scheduled to be enrolled at no fewer than 2 study sites in China. After providing written informed consent, all subjects will undergo screening assessments.…
Sponsor: Shanghai Vision Science Engineer Medical Equipment Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingEpstein-Barr virus (EBV) is a double-stranded DNA virus belonging to the Gammaherpesvirinae subfamily of Herpesviridae. It primarily infects B cells and pharyngeal epithelial cells, and can also infect NK cells and T cells. EBV is closely associated with a variety of hematologica…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take on stomach cancer in new trial
Disease control Not yet recruitingTo evaluate the safety and tolerability of CT0494BCP following infusion in participants with advanced gastric/esophagogastric junction adenocarcinoma (G/GEJA) To evaluate preliminary efficacy of CT0494BCP To evaluate the cellular metabolism kinetics of CT0494BCP The investigation…
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Double immune attack: new combo aims to boost CAR-T success in tough lymphoma
Disease control Not yet recruitingThe Double-T trial is a prospective, randomized, single-arm, open-label, multicenter phase II trial investigating a double T-cell therapy strategy, which includes glofitamab with gemcitabine/oxaliplatin (Glofi-Gem/Ox) prior to and glofitamab monotherapy consolidation after standa…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can surgery save the kidneys in deep endometriosis?
Knowledge-focused Recruiting nowEndometriosis is a chronic estrogen-dependent disease characterized by the presence and growth of endometrium-like tissue outside the uterine cavity. This ectopic endometrial tissue induces a chronic local and systemic inflammatory response, resulting in the most common manifest…
Sponsor: Charles University, Czech Republic • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Can a glowing dye and a gamma probe spare testicular cancer patients from chemo?
Disease control Recruiting nowTesticular seminoma is a malignant tumor with a very high probability of cure. Current treatment approaches provide excellent long-term cancer outcomes. However, some standard treatments, including radiotherapy and platinum-based chemotherapy, may cause side effects both during t…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Electric baths may reawaken hand strength after stroke
Disease control CompletedThis study evaluates the therapeutic effects of underwater electrical faradic stimulation delivered via a four-cell hydrotherapy bath on hand grip strength and upper limb motor recovery in subacute post-stroke hemiplegic patients.
Sponsor: Deraya University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC